Product Information | |||||
Protein full name | Cyclin-dependent kinase inhibitor 1B | ||||
Synonyms | CDKN1B, CDKN4, KIP1, MEN1B, MEN4, P27KIP1, cyclin-dependent kinase inhibitor 1B, cyclin dependent kinase inhibitor 1B,p27Kip1, Cdki1b, p27, Cyclin-dependent kinase inhibitor p27, P27-like cyclin-dependent kinase inhibitor | ||||
Immunogen | Recombinant protein corresponding to Human p27 KIP 1 | ||||
Uniprot ID | P46527 | ||||
Isotype | IgG, κ | ||||
Clone Number | SB289 | ||||
Purity | Affinity purification | ||||
Subcellular location | Nucleus, Cytoplasm, Endosome | ||||
Predicted MW. / Observed MW. | 22 kDa / 27 kDa | ||||
Applications | Species | Dilution | Positive Tissue | ||
WB | Human, Mouse, Rat | 1: 500-1: 1000 | liver, brain, HeLa | ||
IHC/IF | Human, Rat | 1: 500-1: 1000 | colon cancer, brain, tonsil | ||
Storage | |||||
Storage | Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. | ||||
Storage Buffer | PBS with 0.15% ProClin300, 100 μg/mL BSA and 50% glycerol. | ||||
background | |||||
CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer. | |||||
Images | |||||
|
|
| |||
WB analysis of p27 KIP 1(GB15517). | IHC analysis of p27 KIP 1(GB15517). | IF analysis of p27 KIP 1(GB15517)red. | |||
For Research Use Only!
Use collapsible tabs for more detailed information that will help customers make a purchasing decision.
Ex: Shipping and return policies, size guides, and other common questions.